Glycoprotein News and Research

RSS

MVA SARS-CoV-2 vaccine candidate shows strong immunogenicity in preclinical trials

A new study reports the preclinical testing of a recombinant MVA (rMVA) candidate vaccine against SARS-CoV-2, the agent that is causing the current COVID-19 pandemic.

14 Jan 2021

Could intranasal SARS-CoV-2 vaccines be a practical alternative to intramuscular shots?

The unchecked advance of COVID-19 has made it a top public health priority to produce a vaccine capable of inducing a safe and powerful protective response against its causative pathogen: SARS-CoV-2. An encouraging new study shows the immunogenicity, safety, and protective efficacy, of a Newcastle disease virus (NDV)-based intranasal vector vaccine in animal studies.

14 Jan 2021

Researchers map genetic changes that may have facilitated SARS-CoV-2’s jump from bats to humans

Researchers from the University of Cambridge and the Pirbright Institute in the UK have identified key genetic changes in SARS-CoV-2 that may be responsible for the virus’s jump from bats to humans. The team also determined which animals contain cellular receptors that allow the virus to enter cells more effectively, zoning in on potential animals that acted as an intermediary host in facilitating SARS-CoV-2’s zoonosis.

13 Jan 2021

New N501 SARS-CoV-2 mutation may have been circulating in Italy since August 2020

A recent study shows that mutated SARS-CoV-2 strains with a substitution at position 501 might have circulated unnoticed even before the end of September 2020, when the rapid emergence of B.1.1.7 lineage (carrying the N501Y mutation) was initially reported.

13 Jan 2021

Structure of SARS-CoV-2 cytoplasmic tail uncovered

The virus's cytosolic tail also interacts with the host cell to promote its entry into the endoplasmic reticulum (ER). A new study appearing on the bioRxiv preprint server elucidates the conformation of this region of the virus, which will help understand how its form is related to its function in viral entry.

12 Jan 2021

Effect of mutations in the South African SARS-CoV-2 variant on transmission and neutralization

One such strain is the South African 501.V2 and UK B1.1.7 strains, which have been isolated from many countries and seem to spread faster than the ancestral strain. A preprint that recently appeared on the bioRxiv server reports the computational structure of this strain and the possible effect of the mutations on infectivity and neutralization.

12 Jan 2021

Discovery of SARS-CoV-2 neutralizing antibodies from a naïve human Ab library

Now, a new preprint research paper published on the bioRxiv server shows how closely the antibodies formed in exposed humans resemble the germline antibody molecules. This could lead to the development of novel therapeutics to counter the pandemic.

12 Jan 2021

Antibody recognition of linear SARS-CoV-2 epitopes preserved in mutated B.1.1.7 strain

In a recent medRxiv research paper, the US scientists examined the effects of non-synonymous mutations in the circulating B.1.1.7 strain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on linear antibody epitope signal for viral spike glycoprotein and nucleoprotein – and demonstrated that mutations should not result in immune evasion.

11 Jan 2021

Study shows P681H mutation is becoming globally prevalent among SARS-CoV-2 sequences

In a recent bioRxiv preprint study, researchers from the University of Hawaii showed that the S gene of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuously mutating according to the sequence and phylogenetic analysis.

10 Jan 2021

Naturally selected mutations of SARS-CoV-2 easily duplicated in vitro

In a recent and timely paper, currently available on the bioRxiv preprint server, researchers from Israel and France demonstrated how in vitro evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain (RBD) follows contagious mutation spread – but can also generate an efficient infection inhibitor.

10 Jan 2021

High-affinity SARS-CoV-2 RBD drives mutation spread, forms basis of new COVID-19 inhibitor

Now, an intriguing recent study appeared on the bioRxiv * preprint server describes the use of in vitro evolution to elicit affinity maturation of the viral receptor-binding domain (RBD) of the spike protein to bind the host cell angiotensin-converting enzyme 2 (ACE2) with greater affinity.

7 Jan 2021

Antibodies and inflammatory markers are pervasive in colostrum of SARS-CoV-2 infected women

A recent study, currently available on the medRxiv* preprint server, is among the first to reveal the presence of antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in colostrum and to demonstrate elevated cytokine levels in colostrum from women exposed to the virus.

7 Jan 2021

Study shows durable specific humoral immunity against SARS-CoV-2 after mild or asymptomatic infection

As a part of the COMMUNITY (COVID-19 Immunity) study, researchers from Sweden reveal long-lasting IgG neutralizing antibody response against spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the vast majority of convalescent individuals – even after asymptomatic or mild infection. Their results are currently available on medRxiv* preprint server.

6 Jan 2021

Neutralization antibodies affected by only a few mutations to the SARS-CoV-2 receptor-binding domain

In a recent bioRxiv* preprint paper, US researchers mapped in detail how mutations to the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affected antibody binding in convalescent human serum – and revealed that it is influenced by mutations at only a handful of dominant epitopes.

6 Jan 2021

Glycoprotein News and Research

MVA SARS-CoV-2 vaccine candidate shows strong immunogenicity in preclinical trials

Could intranasal SARS-CoV-2 vaccines be a practical alternative to intramuscular shots?

Researchers map genetic changes that may have facilitated SARS-CoV-2’s jump from bats to humans

New N501 SARS-CoV-2 mutation may have been circulating in Italy since August 2020

Structure of SARS-CoV-2 cytoplasmic tail uncovered

Effect of mutations in the South African SARS-CoV-2 variant on transmission and neutralization

Discovery of SARS-CoV-2 neutralizing antibodies from a naïve human Ab library

Antibody recognition of linear SARS-CoV-2 epitopes preserved in mutated B.1.1.7 strain

Study shows P681H mutation is becoming globally prevalent among SARS-CoV-2 sequences

Naturally selected mutations of SARS-CoV-2 easily duplicated in vitro

High-affinity SARS-CoV-2 RBD drives mutation spread, forms basis of new COVID-19 inhibitor

Antibodies and inflammatory markers are pervasive in colostrum of SARS-CoV-2 infected women

Study shows durable specific humoral immunity against SARS-CoV-2 after mild or asymptomatic infection

Neutralization antibodies affected by only a few mutations to the SARS-CoV-2 receptor-binding domain

FDA approves first oral drug for treating adult patients with advanced prostate cancer

Remdesivir inhibits SARS-CoV-2 replication by preventing RdRp-mediated RNA translocation

Rapid point-of-care lateral flow assay to assess the neutralizing activity of plasma against SARS-CoV-2

SARS-CoV-2 spike deletion ΔH69/ΔV70 shows repeated emergence and spread

Autoimmune condition biomarkers promote SARS-CoV-2 viral entry, study finds

Emergence of resistant SARS-CoV-2 variant in immunocompromised patient following therapeutic antibody use

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News